Multiprotein-engineered cells secreting a multispecific antibody
US-2024344030-A1 · Oct 17, 2024 · US
Methods for enhancing hematopoietic stem/progenitor cell engraftment
US9051548B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9051548-B2 |
| Application number | US-201013147710-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 3, 2010 |
| Priority date | Feb 3, 2009 |
| Publication date | Jun 9, 2015 |
| Grant date | Jun 9, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Described herein are methods for enhancing engraftment of hematopoietic stem and progenitor cells using farnesyl compounds identified using a zebrafish model of hematopoietic cell engraftment. The compounds can be used to treat hematopoietic stem cells ex vivo prior to transplantation of the cells. Alternatively, the compounds can be administered to an individual undergoing cell transplantation.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for enhancing hematopoietic cell engraftment in a subject, the method comprising: (a) contacting a population of hematopoietic cells with a compound selected from the group consisting of: S-farnesyl-L-cysteine methyl ester (FCME), and farnesylthioacetic acid (FTA), and (b) administering treated cells from step (a) to a subject in need thereof, wherein the engraftment of said hematopoietic cells treated with said compound is increased compared to engraftment of a population of untreated hematopoietic cells. 2. The method of claim 1 , wherein said compound is S-farnesyl-L-cysteine methyl ester (FCME). 3. The method of claim 1 , wherein the compound is farnesylthioacetic acid (FTA). 4. The method of claim 1 , wherein said population of hematopoietic cells is derived from cord blood. 5. The method of claim 1 , wherein said population of hematopoietic cells is derived from bone marrow. 6. The method of claim 1 , wherein said population of hematopoietic cells is derived from blood. 7. The method of claim 1 , wherein said population of hematopoietic cells are isolated cells. 8. The method of claim 1 , wherein said population of hematopoietic cells is a heterogeneous or homogeneous population of cells. 9. The method of claim 1 , wherein said contacting step is performed on ex vivo cells in culture. 10. The method of claim 1 , wherein said subject is a human subject. 11. The method of claim 1 , wherein said hematopoietic cells are hematopoietic stem cells. 12. The method of claim 1 , wherein said hematopoietic cells are hematopoietic progenitor cells.
Assignees
Inventors
Classifications
Esters, e.g. nitroglycerine, selenocyanates · CPC title
- A61K35/28Primary
Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells · CPC title
of sulfoxy acids or sulfur analogues thereof · CPC title
Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60) · CPC title
Lipids · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9051548B2 cover?
- Described herein are methods for enhancing engraftment of hematopoietic stem and progenitor cells using farnesyl compounds identified using a zebrafish model of hematopoietic cell engraftment. The compounds can be used to treat hematopoietic stem cells ex vivo prior to transplantation of the cells. Alternatively, the compounds can be administered to an individual undergoing cell transplantation.
- Who is the assignee on this patent?
- Zon Leonard I, Li Pulin, Childrens Medical Center
- What technology area does this patent fall under?
- Primary CPC classification A61K35/28. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jun 09 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).